Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study
Authors:
- 29 October 2014
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 44 (2) , 118-124
Abstract
Objectives: Insight into the most important inflammatory pathways in ankylosing spondylitis (AS) could be of importance in risk stratification and the development of treatment strategies. Therefore, we aimed to compare circulating levels of inflammatory biomarkers between AS patients and controls, and explore associations between these biomarkers and clinical measures of disease activity. Method: In a cross-sectional study, 143 AS patients were compared with 124 population controls. Blood samples were analysed by immunoassays for interleukin (IL)-6, IL-17a, IL-23, soluble tumour necrosis factor receptor 1 (sTNF-R1) and 2 (sTNF-R2), and osteoprotegerin (OPG). Disease activity was measured by the AS Disease Activity Score (ASDAS) and the Bath AS Disease Activity Index (BASDAI). Results: Analysis of covariance (ANCOVA) demonstrated elevated plasma levels of sTNF-R1 [geometrical mean 0.94 (95% CI 0.88–1.00) vs. 0.83 (95% CI 0.78–0.89) ng/mL, p < 0.01] and OPG (2.3, 95% CI 2.1–2.4 vs. 2.0, 95% CI 1.9–2.2 ng/mL, p = 0.02) and, although not significant, of IL-23 (122, 95% CI 108–139 vs. 106, 95% CI 93–120 pg/mL, p = 0.07) in AS patients vs. controls. More AS patients had a high level of sTNF-R2 than controls (22 vs. 1, p < 0.01). No differences between the groups were seen for IL-6 and IL-17a. In patients, no significant associations were seen between inflammatory markers and disease activity measures after adjusting for personal characteristics. Conclusion: Significantly higher plasma levels of sTNF-R1, sTNF-R2, and OPG and numerically but non-significantly higher levels of IL-23 were found in AS patients compared to controls, indicating that these cytokines and cytokine receptors are important inflammatory pathways. Clinical measures of disease activity were not significantly correlated with circulating inflammatory markers.Keywords
This publication has 37 references indexed in Scilit:
- Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 2014
- In Situ Analysis of Interleukin–23– and Interleukin‐12–Positive Cells in the Spine of Patients With Ankylosing SpondylitisArthritis & Rheumatism, 2013
- SpondyloarthritisThe Lancet, 2011
- Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitisClinical Rheumatology, 2010
- Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitorsClinical Rheumatology, 2010
- Serum leptin levels correlate with interleukin‐6 levels and disease activity in patients with ankylosing spondylitisScandinavian Journal of Rheumatology, 2007
- Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced casesAnnals of the Rheumatic Diseases, 2006
- Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitisClinical Rheumatology, 2006
- Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitisArthritis & Rheumatism, 1995
- SERUM CYTOKINES (IL-6, TNF-α, IL-1β AND IFN-γ) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWEEN SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITYRheumatology, 1994